Verrica Pharmaceuticals reported a net loss of $35.2 million for the first nine months of 2026, driven by increased R&D and SG&A expenses. The company issued a going concern warning due to an accumulated deficit of $360.2 million and limited cash reserves of $14.4 million, though it recently secured a credit agreement for up to $27.5 million.
Verrica Pharmaceuticals reported record Q3 2026 YCANTH net product revenue of $5.7 million, a 57.9% increase year-over-year, and total revenue of $6.9 million. The company completed enrollment in its first Phase 3 pivotal trial for common warts and unlocked $27.5 million in non-dilutive growth capital by meeting credit facility milestones.
Term
Q3 2026
“Verrica made progress in growing our commercial YCANTH business for molluscum contagiosum while advancing our late-stage pipeline for two of the most prevalent skin diseases, and extending our cash runway during the third quarter.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer
“Under our current operating plan, including finishing the global Phase 3 program in common warts, and the full utilization of our credit facility, we now have sufficient liquidity to fund operations through data readouts for both pivotal trials of the common warts program.”
Jayson Rieger, PhD, MBA, President and Chief Executive Officer